Tag: Axim Biotechnologies

Avatar photoJack SmithMarch 19, 2018
canchew-cbd-gum.jpg
BusinessFinancial

AXIM Biotechnologies Reports Fiscal 2017 Results, Says Making “Solid Progress”

4min00
AXIM Biotechnologies (AXIM) reported fiscal 2017 full-year results, with CEO Dr. George Anastassov highlighting “solid progress” the company is making on its clinical pipeline, including it getting a mass-market chewing gum to help cancer patients with nausea and vomiting. The company said it ended the year with $2.1 million in cash, losing 8 cents a share, […]
CONTINUE READING
Avatar photoStaffNovember 22, 2017
canchew-cbd-gum.jpg
Financial

Revenues Flat, Losses Trimmed For Axim Biotechnologies Third Quarter

4min00
Axim Biotechnologies Inc. (AXIM) delivered its third-quarter earnings with revenues essentially flat, but losses were trimmed as the research and development expenses increased dramatically. Revenues weren’t even mentioned in the company’s press release regarding its earnings for the quarter ending September 30, 2017. Revenues were recorded at $9,758, a slight increase over last year’s $9,600. […]
CONTINUE READING

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis

READ MORE
Company